MedTrace Logo

Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

NCT03664843 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2018-11-13

No results posted yet for this study

Summary

Conduct a prospective study in multicenter to confirm the value of circulating tumor DNA in longitudinal monitoring of stage III-IV lung cancer patients.

Conditions

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    collaborator OTHER

  • Affiliated Hospital of Hebei University

    collaborator OTHER

  • Hebei Medical University Fourth Hospital

    collaborator OTHER

  • Xingtai People's Hospital

    collaborator OTHER

  • First Hospital of Shijiazhuang City

    lead OTHER

Principal Investigators

  • Yan Zhang, M.D. · The First Hospital of Shijiazhuang

  • Jun Wang, M.D. · Peking University People's Hospital

  • Kezhong Chen, M.D. · Peking University People's Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-09
Primary Completion
2020-05-01
Completion
2020-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03664843 on ClinicalTrials.gov